Naltrexone–bupropion for managing overweight and obesity

Equality Impact Assessment (Guidance development) (PDF 253 KB)

Appeal

Orexigen Therapeutics : Appeal letter (PDF 615 KB)

Orexigen Therapeutics : Scrutiny letter (PDF 429 KB)

Orexigen Therapeutics : Response to scrutiny letter (PDF 233 KB)

Orexigen Therapeutics : Final scrutiny letter (PDF 408 KB)

Appeal decision (PDF 255 KB)

Final appraisal determination

Final appraisal determination document (PDF 292 KB)

Committee papers ACM2 (PDF 2.54 MB)

Public committee slides ACM2 (PDF 434 KB)

Draft guidance

Appraisal consultation document (PDF 279 KB)

Appraisal consultation document (PDF 21.26 MB)

Public committee slides (PDF 354 KB)

Public committee slides (PDF 546 KB)

Final matrix (PDF 41 KB)

NICE's response to comments on the draft scope and provisional matrix (PDF 144 KB)

Final scope (PDF 107 KB)

Equality impact assessment (Scoping) (PDF 120 KB)

Draft scope (post-referral) (PDF 114 KB)

Provisional matrix (post-referral) (PDF 54 KB)

Draft scope (pre-referral) (PDF 111 KB)

Provisional matrix (pre-referral) (PDF 54 KB)

Obesity, overweight with risk factors - naltrexone-bupropion (prolonged release): draft scope for consultation (pre-referral) - March 2014 (PDF 111 KB)

Obesity, overweight with risk factors - naltrexone-bupropion (prolonged release): provisional matrix (pre-referral) - March 2014 (PDF 54 KB)